Halozyme

J&J’s next-gen Darzalex sparks drug delivery royalties battle
J&J’s next-gen Darzalex sparks drug delivery royalties battle
Fierce Pharma
JNJ
Darzalex
Genmab
Halozyme
Flag link:
After Ending Cancer Drug Program, Halozyme Predicts Profits in 2020
After Ending Cancer Drug Program, Halozyme Predicts Profits in 2020
Xconomy
Halozyme
clinical trials
drug delivery
Enhanze
Flag link:
Halozyme drops PFS co-primary endpoint from PEGPH20 phase 3
Halozyme drops PFS co-primary endpoint from PEGPH20 phase 3
Fierce Biotech
Halozyme
clinical trials
PEGPH20
metastatic prostate cancer
Flag link:
Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?
Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?
Motley Fool
Halozyme
Inovalon
Teva Pharmaceutical
Unitedhealthcare Group
Roche
Bristol-Myers Squibb
Flag link:
Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take
Bristol To Pay Halozyme $105 Million To Make New Cancer Drugs Easier To Take
Forbes
Bristol-Myers Squibb
Halozyme
Opdivo
Flag link:
Halozyme Cancer Drug Does Well in Phase 2
Halozyme Cancer Drug Does Well in Phase 2
Investopedia
Halozyme
pancreatic cancer
clinical trials
PEGPH20
Eli Lilly
Celgene
gemcitabine
Abraxane
Flag link:
AbbVie Ends Halozyme Development Deal
AbbVie Ends Halozyme Development Deal
Investopedia
AbbVie
Halozyme
tnf-alpha
drug development
drug delivery
Flag link:
Halozyme shares drop after AbbVie punts a failed program; Celgene buys another cancer drug
Halozyme shares drop after AbbVie punts a failed program; Celgene buys another cancer drug
Endpoints
Halozyme
AbbVie
Celgene
marizomib
Flag link:
Halozyme Therapeutics reports 3Q loss
Halozyme Therapeutics reports 3Q loss
Yahoo/AP
earnings
Halozyme
Flag link:
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
Yahoo
FDA
Genentech
Halozyme
rituximab
blood cancer
Flag link:
3 Top Biopharma Movers of the Past Week
3 Top Biopharma Movers of the Past Week
24/7 Wall St
Vitae
Juno Therapeutics
Halozyme
Flag link:
Halozyme Therapeutics beats 4Q profit forecasts
Halozyme Therapeutics beats 4Q profit forecasts
Yahoo/AP
Halozyme
earnings
Flag link:
4 Top BioPharma Movers of the Past Week
4 Top BioPharma Movers of the Past Week
24/7 Wall St
Anavex
Affymetrix
Thermofisher
Halozyme
Flag link:
Eli Lilly taps Halozyme in an $825M delivery deal
Eli Lilly taps Halozyme in an $825M delivery deal
Fierce Biotech
Eli Lilly
Halozyme
drug delivery
Enhanze
Flag link:
3 Midsize Drug Stocks Moving On Q3 Reports
3 Midsize Drug Stocks Moving On Q3 Reports
Investors.com
Jazz Pharmaceuticals
Depomed
Halozyme
Flag link:
3 Biotechs That Play Well with Others
3 Biotechs That Play Well with Others
Motley Fool
Ophthotech
Halozyme
Portola
Flag link:
Why Shares of Halozyme Therapeutics Inc. Plunged 24% in August
Why Shares of Halozyme Therapeutics Inc. Plunged 24% in August
Motley Fool
Halozyme
PEGPH20
AbbVie
Flag link:
Eisai and Halozyme Sign Collaboration Agreement to Investigate Halaven® (Eribulin) and PEGPH20 in Metastatic Breast Cancer
Eisai and Halozyme Sign Collaboration Agreement to Investigate Halaven® (Eribulin) and PEGPH20 in Metastatic Breast Cancer
Yahoo
Eisai
Halozyme
metastatic breast cancer
PEGPH20
Halaven
Flag link:
Halozyme adds AbbVie to its roster of Big Pharma R&D collaborators
Halozyme adds AbbVie to its roster of Big Pharma R&D collaborators
Fierce Biotech
Halozyme
AbbVie
R&D
Flag link:
Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients
Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients
Yahoo
Halozyme
PEGPH20
ASCO
metastatic pancreatic cancer
Flag link:

Pages